CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma

Cancer Research

Volumn 63, Issue 2, 2003, Pages 394-399

  Sandler, Anthony D ^a,d   Chihara, Hiroshi ^b   Kobayashi, Gen ^a   Zhu, Xiaoyan ^a   Miller, Michal A ^a   Scott, David L ^a   Krieg, Arthur M ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c PFIZER INC   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; OLIGODEOXYNUCLEOTIDE; OLIGONUCLEOTIDE; TUMOR ANTIGEN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CPG ISLAND; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC TRANSDUCTION; IMMUNE RESPONSE; IMMUNOTHERAPY; IRRADIATION; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIGENS, CD3; APOPTOSIS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CPG ISLANDS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED A; NEUROBLASTOMA; OLIGONUCLEOTIDES; TH1 CELLS; TRANSFECTION;

EID: 0037439696     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Neuroblastoma. In: M. I. Rowe, J. A. O'Neill, J. L. Grosfeld, E. W. Fonkalsrud, and A. G. Coran (eds.), Essentials of Pediatric Surgery, pp. 249-259. St. Louis: Mosby, 1995.
2. Pritchard, J., and Hickman, J. A. Why does stage 4s neuroblastoma regress spontaneously? [see comments] Lancet. 344: 869-870, 1994.
3. Gestblom, C., Hoehner, J. C., and Pahlman, S. Proliferation and apoptosis in neuroblastoma: subdividing the mitosis-karyorrhexis index. Eur. J. Cancer, 31A: 458-463, 1995.
4. Medzhitov, R., and Janeway, C. A., Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell, 91: 295-298, 1997.
5. Carroll, M. C., and Prodeus, A. P. Linkages of innate and adaptive immunity. Curr. Opin. Immunol., 10: 36-40, 1998.
6. Stahl, P. D., and Ezekowitz, R. A. The mannose receptor is a pattern recognition receptor involved in host defense. Curr. Opin. Immunol., 10: 50-55, 1998.
7. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akira, S. A toll-like receptor recognizes bacterial DNA [erratum published Nature, 409: 646, 2001]. Nature (Lond.), 408: 740-744, 2000.
8. Flynn, J. L., Goldstein, M. M., Chan, J., Triebold, K. J., Pfeffer, K., Lowenstein, C. J., Schreiber, R., Mak, T. W., and Bloom, B. R. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity, 2: 561-572, 1995.
9. Krieg, A. M., Yi, A. K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G., and Klinman, D. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (Lond.), 374: 546-549, 1995.
10. Krieg, A. M. An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J. Lab. Clin. Med., 128: 128-133, 1996.
11. Mocci, S., Dalrymple, S. A., Nishinakamura, R., and Murray, R. The cytokine stew and innate resistance to L. monocytogenes. Immunol. Rev., 158: 107-114, 1997.
12. Ballas, Z. K., Rasmussen, W. L., and Krieg, A. M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol., 157: 1840-1845, 1996.
13. Hartmann, G., and Krieg, A. M. Mechanism and function of a newly identified CpG DNA motif in human primary cells. J. Immunol., 164: 944-952, 2000.
14. Hartmann, G., Weeratna, R. D., Ballas, Z. K., Payette, P., Blackwell, S., Suparto, I., Rasmussen, W. L., Waldschmidt, M., Sajuthi, D., Purcell, R. H., Davis, H. L., and Krieg, A. M. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol., 164: 1617-1624, 2000.
15. Jones, T. R., Obaldia, N., III, Gramzinski, R. A., Charoenvit, Y., Kolodny, N., Kitov, S., Davis, H. L., Krieg, A. M., and Hoffman, S. L. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine, 17: 3065-3071, 1999.
16. Davis, H. L., Suparto, I. I., Weeratna, R. R., Jumintarto, Iskandriati, D. D., Chamzah, S. S., Maruf, A. A., Nente, C. C., Pawitri, D. D., Krieg, A. M., Heriyanto, Smits, W., and Sajuthi, D. D. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine, 18: 1920-1924, 2000.
17. Weeratna, R. D., McCluskie, M. J., Xu, Y., and Davis, H. L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine, 18: 1755-1762, 2000.
18. Brazolot Millan, C. L., Weeratna, R., Krieg, A. M., Siegrist, C. A., and Davis, H. L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. USA, 95: 15553-15558, 1998.
19. Lipford, G. B., Sparwasser, T., Zimmermann, S., Heeg, K., and Wagner, H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J. Immunol., 165: 1228-1235, 2000.
20. Jakob, T., Walker, P. S., Krieg, A. M., Udey, M. C., and Vogel, J. C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J. Immunol., 161: 3042-3049, 1998.
21. Sparwasser, T., Koch, E. S., Vabulas, R. M., Heeg, K., Lipford, G. B., Ellwart, J. W., and Wagner, H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol., 28: 2045-2054, 1998.
22. Hartmann, G., Weiner, G., and Krieg, A. M. CpG DNA: A potent signal for growth, activation and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA, 96: 9305-9310, 1999.
23. Brunner, C., Seiderer, J., Schlamp, A., Bidlingmaier, M., Eigler, A., Haimerl, W., Lehr, H. A., Krieg, A. M., Hartmann, G., and Endres, S. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic tumor antigen-specific immune responses in vivo. J. Immunol., 165: 6278-6286, 2000.
24. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
25. Liu, H-M., Newbrough, S. E., Bhatia, S. K., Dahle, C. E., Krieg, A. M., and Weiner, G. J. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood, 92: 3730-3736, 1998.
26. Yi, A. K., and Krieg, A. M. CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of IκBα and IκBβ and sustained activation of nuclear factor-κB/c-Rel. J. Immunol., 160: 1240-1245, 1998.
27. Elzey, B. D., Siemens, D. R., Ratliff, T. L., and Lubaroff, D. M. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer, 94: 842-849, 2001.
28. Halpern, M. D., Kurlander, R. J., and Pisetsky, D. S. Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α. Cell. Immunol., 167: 72-78, 1996.
29. Krieg, A. M., Love-Homan, L., Yi, A. K., and Harty, J. T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol., 161: 2428-2434, 1998.
30. Klein, G., Sjogren, H. O., Klein, E., and Hellstrom, K. E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res., 20: 1561-1572, 1960.
31. Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. C., Liebster, L., Lam, P., Mentzer, S., Singer, S., Tanabe, K. K., Cosimi, A. B., Duda, R., Sober, A., Bhan, A., Daley, J., Neuberg, D., Parry, G., Rokovich, J., Richards, L., Drayer, J., Berns, A., Clift, S., Cohen, L. K., Mulligan, R. C., and Dranoff, G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA, 95: 13141-13146, 1998.
32. Strome, S. E., Voss, S., Wilcox, R., Wakefield, T. L., Tamada, K., Flies, D., Chapoval, A., Lu, J., Kasperbaur, J. L., Padley, D., Vile, R., Gastineau, D., Wettstein, P., and Chen, L. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res., 62: 1884-1889, 2002.
33. Bausero, M. A., Panoskaltsis-Mortari, A., Blazar, B. R., and Katsanis, E. Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-γ. J. Immunother. Emph. Tumor Immunol., 19: 113-124, 1996.
34. Yoshida, H., Enomoto, H., Kawamura. K., Takenaga, K., Tanabe, M., Ohnuma, N., Sakiyama, S., and Tagawa, M. Antitumor vaccine effect of irradiated murine neuroblastoma cells producing interleukin-2 or granulocyte macrophage-colony stimulating factor. Int. J. Oncol., 13: 73-78, 1998.
35. Takamizawa, S., Okamoto, S., Wen, J., Kimura, K., Bishop, W., and Sandler, A. D. Over-expression of Fas-Ligand by neuroblastoma: a novel mechanism of tumor cell killing. J. Pediatr. Surg., 35: 375-379, 2000.
36. Jaffee, E., Hrubann, R., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P., Goemann, M., Coleman, J., Grochow, L., Donehower, R., Lillemoe, K., O'Rielly, S., Abrams. R., Pardoll, D., Cameron, J., Yeo, C. Novel allogenic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. J. Clin. Oncol., 19: 145-156, 2001.
37. Weiner, G. J. Immunostimulatory DNA sequences and cancer therapy. Springer Semin. Immunopathol., 22: 107-116, 2000.